Sanofi Recalls Some Batches of Combiflam in India
Sanofi (SASY.PA) is recalling some batches of its painkiller Combiflam in India after the country's drugs regulator found the lots were substandard, the French drugmaker's local unit (SANO.NS) said on Thursday.
India's Central Drugs Standard Control Organisation (CDSCO) said in notices posted on its website in February and April that it had found some batches of Combiflam to be "not of standard quality" as they failed disintegration tests.
Disintegration tests are used to test the time it takes for tablets and capsules to break down inside the body, and are used as a quality-assurance measure in pharmaceuticals, according to the U.S. Food and Drug Administration.
India's Central Drugs Standard Control Organisation (CDSCO) said in notices posted on its website in February and April that it had found some batches of Combiflam to be "not of standard quality" as they failed disintegration tests.
Disintegration tests are used to test the time it takes for tablets and capsules to break down inside the body, and are used as a quality-assurance measure in pharmaceuticals, according to the U.S. Food and Drug Administration.